Calcimedica, Inc. insider trading

Every open-market purchase and sale by Calcimedica, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchases, 5 years $199,178 1 trade by 1 insider 3 months later: median −44.4% (−49.1% vs S&P 500) Insider sales, 5 years $0 0 trades by 0 insiders

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.

Calcimedica, Inc. insider open-market trades
Date	Insider	Trade	Shares	Price	Value	1M after	3M after	6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Calcimedica, Inc.’s insiders pay?

From September 29, 2020 to June 29, 2026, 11 insiders reported 40 open-market purchases and 1 sale not made under a pre-set plan in Calcimedica, Inc. Twelve months after each purchase was reported, the shares were −77.8% against the S&P 500 on average (median −77.8%), over 1 purchase with a full year of prices; 0% beat the index. That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on January 26, 2024 into $5,223 by November 2, 2026, −21.0% a year. It held shares 36% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $13,370 (+11.1% a year), and held throughout $16,028 (+18.7%).

Copying Calcimedica, Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Calcimedica, Inc.'s insiders from January 26, 2024, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 36% of the time.

Calcimedica, Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	Sales	12 months after their sales	Latest report
Roberts Eric W	CHIEF BUSINESS OFFICER	17	—	—	0	—	September 15, 2025
Middleton Fred A	Director	5	−77.8% (1)	0%	0	—	June 29, 2026
Wilson Robert N	Director	5	—	—	0	—	July 18, 2025
Hebbar Sudarshan	Chief Medical Officer	4	—	—	0	—	August 21, 2025
Leheny A. Rachel	CHIEF EXECUTIVE OFFICER	4	—	—	0	—	November 1, 2024
Blackstone Clarus III L.L.C.	10% owner	1	—	—	0	—	October 1, 2020
Breuil Robert S	Chief Financial Officer	0	—	—	1	—	September 24, 2021
Deerfield Healthcare Innovations Fund, L.P.	10% owner	1	—	—	0	—	October 1, 2020
Orbimed Advisors LLC	10% owner	1	—	—	0	—	September 29, 2020
Sanderling Venture Partners VI LP	10% owner	1	—	—	0	—	November 5, 2024
Shaffer Christy L	Director	1	—	—	0	—	September 29, 2020

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

← Back to Calcimedica, Inc. · Funds · Politicians